State health commissioner studies gene therapy innovation support

File SF4189 ("State health commissioner studies gene therapy innovation support") is before the Minnesota Legislature and has not been decided. Latest step (April 7, 2026): Author added.

Minnesota file SF4189, before the Minnesota Legislature. Still to be decided as of 2026-04-07.

What it does

No immediate change to your healthcare or treatment access This bill requires the Minnesota Commissioner of Health to study and report on how the state can support cell and gene therapy innovation; it does not fund treatments, change eligibility, or alter coverage.

The bigger picture

May inform future Minnesota rare disease policy and biotech incentives The report could lead to future legislation on tax credits, licensing streamlines, research grants, or partnerships that position Minnesota to attract or expand gene therapy development and clinical access for patients with rare genetic conditions.

What to watch

Study findings do not guarantee funding or policy action The report's recommendations are advisory only; the legislature would need to pass separate bills and appropriate funds to actually implement any changes, and timeline for action is uncertain.

Official summary

Commissioner of health direction to study and report on activities to support innovations in cell and gene therapy to treat rare diseases

Read the official record for SF4189

See everything up for a vote · This week in Minnesota · See what we have filed with the clerk